Feline Calicivirus Infection

Feline calicivirus (FCV) infection is a highly contagious viral disease of domestic and wild Felidae, characterized primarily by acute upper respiratory tract disease and oral ulceration. The virus, a member of the family Caliciviridae, genus Vesivirus, is a non-enveloped, single-stranded positive-sense RNA virus. FCV is one of the major pathogens involved in feline upper respiratory tract disease (URTD) complex, along with feline herpesvirus-1 (FHV-1). The clinical spectrum ranges from subclinical infection to severe systemic disease, including the virulent systemic feline calicivirus (VS-FCV) variant, which causes high morbidity and mortality. The disease is globally distributed and affects cats of all ages, with kittens and young adults being most susceptible. The virus exhibits high genetic and antigenic diversity, complicating vaccine development and cross-protection. Infection is typically self-limiting in immunocompetent adults, but can be severe in kittens, immunocompromised cats, or those infected with VS-FCV strains. The disease is of significant clinical importance in multi-cat environments such as shelters, catteries, and boarding facilities.

The causative agent is Feline calicivirus (FCV), a non-enveloped, icosahedral virus with a single-stranded positive-sense RNA genome of approximately 7.7 kb. The viral capsid is composed of a single major structural protein (VP1) and a minor structural protein (VP2). The virus is highly mutable, leading to numerous antigenic variants. Transmission occurs via direct contact with infected cats, or indirectly through contaminated fomites (food bowls, litter boxes, bedding, grooming tools), aerosols, and human hands. The virus is shed in oral, nasal, and ocular secretions, and can persist in the environment for weeks to months, especially in organic material. Recovered cats may become persistently infected and shed virus for months to years, serving as a reservoir. The virus primarily targets the oral mucosa, respiratory epithelium, and conjunctiva, but can also replicate in other tissues, particularly in virulent systemic strains. The molecular trigger for disease is the attachment of the viral capsid to host cell receptors, such as feline junctional adhesion molecule A (fJAM-A), followed by receptor-mediated endocytosis and uncoating. The virus then replicates in the cytoplasm, leading to cell lysis and inflammation.

FCV infection is endemic worldwide in domestic cats, with a seroprevalence ranging from 20% to 80% depending on the population. The virus is more prevalent in multi-cat environments, such as shelters, catteries, and breeding colonies, where up to 90% of cats may be seropositive. All breeds and both sexes are equally susceptible, but kittens and young cats (under 1 year) are at higher risk due to waning maternal immunity and lack of prior exposure. The disease is more severe in kittens, especially those between 6 weeks and 6 months of age. There is no seasonal pattern, but outbreaks are more common in environments with high population density and poor hygiene. The virulent systemic (VS-FCV) variant has been reported in outbreaks in the United States, Europe, and Asia, with mortality rates up to 50-60%. The virus is highly contagious, with a basic reproduction number (R0) estimated to be high in susceptible populations. Genetic diversity of FCV is extensive, with multiple strains circulating simultaneously in a population, leading to incomplete cross-protection from vaccines.

The pathogenesis of FCV infection begins with viral entry through the oral, nasal, or conjunctival routes. The virus replicates primarily in the epithelial cells of the oral cavity, respiratory tract, and conjunctiva, causing direct cytopathic effects and cell lysis. This leads to the characteristic vesicular lesions on the tongue, hard palate, and nasal planum, which progress to ulcers. In the respiratory tract, viral replication in the nasal mucosa, trachea, and lungs causes rhinitis, tracheitis, and interstitial pneumonia. The inflammatory response involves infiltration of neutrophils and macrophages, release of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), and oxidative stress. In severe cases, particularly with VS-FCV strains, the virus spreads systemically via the bloodstream, causing viremia and infection of endothelial cells, hepatocytes, pancreatic acinar cells, and alveolar macrophages. This results in widespread vascular damage, disseminated intravascular coagulation (DIC), multi-organ failure, and severe systemic inflammatory response syndrome (SIRS). The virus also induces immunosuppression by transiently depleting T lymphocytes and impairing dendritic cell function, predisposing to secondary bacterial infections. The incubation period is typically 2-6 days, and viral shedding begins 2-3 days after infection and can persist for weeks to months.

Intrinsic risk factors include young age (kittens), immunosuppression (e.g., concurrent FIV or FeLV infection, chronic stress, corticosteroid therapy), and genetic susceptibility (some breeds may have higher susceptibility, though not well-defined). Extrinsic factors include overcrowding, poor ventilation, inadequate sanitation, high population turnover (shelters), and lack of vaccination or incomplete vaccination. Stressful events such as weaning, transport, or surgery can precipitate clinical disease in subclinically infected cats. Concurrent infections with other respiratory pathogens (e.g., feline herpesvirus-1, Bordetella bronchiseptica, Chlamydia felis, Mycoplasma spp.) can exacerbate clinical signs. In multi-cat environments, the presence of persistently infected cats increases the risk of transmission. Poor nutrition and concurrent parasitic infections may also increase susceptibility.

Clinical signs vary depending on the strain and host factors. The classic form is characterized by acute onset of fever (103-105°F), depression, anorexia, sneezing, nasal discharge (serous to mucopurulent), ocular discharge (serous to purulent), conjunctivitis, and oral ulceration. Oral ulcers are typically on the tongue, hard palate, and lips, and may be painful, leading to hypersalivation and dysphagia. In some cases, pneumonia may develop, causing tachypnea, dyspnea, and crackles on thoracic auscultation. The acute phase lasts 7-10 days, with recovery in 2-3 weeks. The virulent systemic form (VS-FCV) presents with high fever (104-106°F), severe depression, anorexia, facial and limb edema, ulcerative dermatitis (especially on the face, ears, and paws), jaundice, and signs of multi-organ failure (hepatic, renal, pancreatic). Subcutaneous edema and skin ulceration are hallmark features. Mortality is high, with death occurring within 1-2 weeks. Chronic infection may lead to persistent oral ulceration, chronic stomatitis, and polyarthritis (limping syndrome) in some cats, characterized by shifting lameness and joint swelling.

Differential diagnoses include: 1) Feline herpesvirus-1 (FHV-1) infection: causes similar upper respiratory signs but typically more severe conjunctivitis and keratitis, and less oral ulceration; diagnosis via PCR or virus isolation. 2) Feline chlamydiosis (Chlamydia felis): primarily causes conjunctivitis, less respiratory signs; PCR or culture. 3) Bordetella bronchiseptica infection: causes coughing and pneumonia; culture or PCR. 4) Feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV) infections: may cause immunosuppression and secondary infections; serology or PCR. 5) Feline panleukopenia virus (FPV): causes severe gastroenteritis and leukopenia, not respiratory signs; PCR or antigen testing. 6) Feline infectious peritonitis (FIP): can cause fever, effusions, and granulomatous lesions; Rivalta test, PCR, histopathology. 7) Calicivirus-associated virulent systemic disease must be differentiated from other causes of severe systemic illness such as sepsis, pancreatitis, and hepatic lipidosis. 8) Oral ulcerative lesions may also be caused by eosinophilic granuloma complex, chronic renal failure (uremic ulcers), or toxic insults (e.g., caustic agents). 9) Polyarthritis may be due to immune-mediated diseases or other infections (e.g., Mycoplasma). 10) Pneumonia may be caused by other viral, bacterial, or fungal agents.

The diagnostic approach begins with a thorough history and physical examination, focusing on vaccination status, exposure to other cats, and clinical signs. A presumptive diagnosis can be made based on typical oral ulcers and upper respiratory signs in a susceptible cat. However, definitive diagnosis requires laboratory confirmation. The algorithm is as follows: 1) Initial triage: assess hydration, respiratory status, and oral lesions. 2) Collect samples for molecular testing: oropharyngeal swabs, conjunctival swabs, and nasal swabs for RT-PCR (reverse transcription polymerase chain reaction) to detect FCV RNA. PCR is highly sensitive and specific and can differentiate FCV from FHV-1. 3) Virus isolation: can be performed on cell culture, but is slower and less commonly used. 4) Serology: paired serum samples for neutralizing antibodies can confirm infection but is not useful for acute diagnosis. 5) In cases of suspected VS-FCV, additional samples from blood, skin lesions, and internal organs (at necropsy) should be collected for PCR and histopathology. 6) Complete blood count (CBC), serum biochemistry, and urinalysis are recommended to assess systemic involvement and rule out other causes. 7) Thoracic radiographs are indicated if pneumonia is suspected. 8) If polyarthritis is present, joint fluid analysis and culture may be performed. 9) In chronic cases, biopsy of oral lesions may be needed to rule out other causes. 10) In outbreak situations, molecular characterization of the strain (e.g., sequencing) may be performed for epidemiological purposes.

Hematology: In uncomplicated cases, CBC may be normal or show mild leukopenia due to lymphopenia. In severe systemic disease, leukopenia (neutropenia and lymphopenia) may be pronounced, and thrombocytopenia may occur due to DIC. Serum biochemistry: Acute phase proteins (e.g., alpha-1 acid glycoprotein) may be elevated. In VS-FCV, elevations in liver enzymes (ALT, AST, ALP), bilirubin, creatinine, and urea may be seen due to hepatic and renal involvement. Electrolyte imbalances (hypokalemia, hyponatremia) may occur due to vomiting or diarrhea. Urinalysis: May show proteinuria, hematuria, or casts in cases of renal involvement. Blood gas analysis: May reveal metabolic acidosis in severe systemic disease. Specific biomarkers: Feline pancreatic lipase immunoreactivity (fPLI) may be elevated if pancreatitis is present. Cardiac troponin I may be elevated in cases of myocarditis. Serology/PCR: RT-PCR on oropharyngeal swabs is the gold standard for diagnosis. Quantitative PCR can assess viral load. Virus isolation is also possible. Serology (neutralizing antibodies) is not useful for acute diagnosis but can be used for epidemiological studies.

Radiography: Thoracic radiographs may reveal an interstitial or alveolar pattern in cases of viral pneumonia. In VS-FCV, abdominal radiographs may show hepatomegaly or renomegaly. Ultrasonography: Abdominal ultrasound may show hepatomegaly, splenomegaly, or pancreatic changes (enlarged, hypoechoic) in systemic disease. Echocardiography: Not routinely indicated, but may be performed if myocarditis is suspected. Computed Tomography (CT): Not commonly used but may be helpful in evaluating chronic rhinitis or pneumonia. Magnetic Resonance Imaging (MRI): Not indicated. Endoscopy: Upper airway endoscopy may be used to evaluate the nasal passages and pharynx, but is not necessary for diagnosis. Fluoroscopy: Not used.

Cytology: Fine needle aspirates of affected organs (e.g., liver, spleen) in VS-FCV may show nonspecific inflammation. Joint fluid analysis in polyarthritis may show increased neutrophils and mononuclear cells. Histopathology: Oral ulcers show epithelial necrosis, vesicle formation, and neutrophilic infiltration. In VS-FCV, histopathology of skin lesions reveals severe vasculitis, thrombosis, and necrosis of the epidermis and dermis. Liver biopsy may show hepatocellular necrosis and inflammation. Lung tissue shows interstitial pneumonia with alveolar damage. Immunohistochemistry (IHC) or in situ hybridization can detect viral antigen or RNA in tissues, confirming the diagnosis.

Treatment is primarily supportive, as there is no specific antiviral therapy approved for FCV. The goals are to maintain hydration, nutrition, and respiratory function, and to prevent secondary bacterial infections. 1) Fluid therapy: Intravenous crystalloids (e.g., lactated Ringer's solution) at maintenance rates (40-60 ml/kg/day) or higher if dehydrated. Add potassium chloride (20-30 mEq/L) if hypokalemia is present. 2) Nutritional support: If anorexic, place a nasoesophageal or esophagostomy tube for enteral feeding. Offer highly palatable, warmed food. 3) Respiratory support: Humidification, nebulization with saline, and coupage may help clear nasal discharge. Use pediatric nasal decongestants (e.g., 0.25% phenylephrine) if severe congestion. 4) Oral care: Chlorhexidine oral rinse (0.12%) or gel may be applied to ulcers. 5) Antibiotics: To prevent or treat secondary bacterial infections, use broad-spectrum antibiotics such as amoxicillin-clavulanate (12.5-25 mg/kg PO q8-12h) or doxycycline (5-10 mg/kg PO q12h). 6) Antiemetics: If vomiting, use maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h). 7) Analgesics: For oral pain, use buprenorphine (0.01-0.02 mg/kg IV/SC/PO q8-12h) or gabapentin (5-10 mg/kg PO q12h). 8) Antiviral therapy: Although not approved, some studies suggest that feline interferon-omega (1 MU/kg SC q24h for 5 days) may reduce clinical signs. 9) In severe VS-FCV, aggressive supportive care with intensive monitoring, blood transfusions if DIC, and vasopressors (e.g., norepinephrine CRI) may be needed. 10) Isolation of affected cats to prevent spread.

The prognosis for uncomplicated FCV infection is generally good, with most cats recovering within 2-3 weeks. Mortality is low (<10%) in otherwise healthy adults. However, kittens, geriatric cats, and immunocompromised cats have a higher risk of severe disease and death. The virulent systemic form has a guarded to poor prognosis, with mortality rates of 50-60% even with intensive care. Negative prognostic indicators include severe leukopenia, thrombocytopenia, multi-organ failure, and lack of response to supportive care. Chronic sequelae such as stomatitis and polyarthritis may occur, affecting long-term quality of life. Recovered cats may become persistently infected and shed virus, but many eventually clear the infection.

Recheck examinations should be scheduled at 7-14 days after initial diagnosis to assess resolution of clinical signs. For cats with severe disease, more frequent monitoring (daily) is required. Serial CBC and biochemistry panels may be indicated to monitor organ function. In cases of VS-FCV, repeat thoracic radiographs and abdominal ultrasound may be needed. Vaccination status should be reviewed, and cats should be vaccinated according to current guidelines (FVRCP vaccine) after recovery. In multi-cat environments, quarantine of new cats for at least 2 weeks is recommended. Long-term management includes minimizing stress, providing good nutrition, and monitoring for chronic complications such as stomatitis.

Pearls: 1) Oral ulcers are a hallmark of FCV and are more common than in FHV-1. 2) VS-FCV should be suspected in cats with fever, edema, and skin ulceration, especially in outbreak situations. 3) PCR is the most sensitive diagnostic test; collect samples early in the disease course. 4) Supportive care is the mainstay; early aggressive fluid therapy and nutritional support improve outcomes. 5) Vaccination reduces severity but does not prevent infection. Pitfalls: 1) Do not rely solely on clinical signs; confirm with PCR. 2) Avoid using corticosteroids, as they can worsen viral shedding and immunosuppression. 3) Do not overlook secondary bacterial infections; use appropriate antibiotics. 4) In VS-FCV, do not delay intensive care; early intervention is critical. 5) Do not assume that vaccinated cats are protected; they can still become infected, albeit with milder signs.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Amoxicillin-clavulanate (Clavamox): 12.5-25 mg/kg PO q8-12h for 7-10 days. 2) Doxycycline: 5-10 mg/kg PO q12h for 7-14 days; give with food to reduce vomiting. 3) Maropitant (Cerenia): 1 mg/kg SC q24h or 2 mg/kg PO q24h for 3-5 days. 4) Ondansetron: 0.5-1 mg/kg IV q12h. 5) Buprenorphine: 0.01-0.02 mg/kg IV/SC/PO q8-12h. 6) Gabapentin: 5-10 mg/kg PO q12h for pain. 7) Feline interferon-omega (Virbagen Omega): 1 MU/kg SC q24h for 5 consecutive days; may be repeated. 8) Chlorhexidine oral rinse (0.12%): apply to ulcers twice daily. 9) For severe systemic disease, consider human recombinant interferon-alpha (30-50 IU/kg PO q24h) but evidence is limited. 10) In cases of DIC, consider heparin (200-300 IU/kg SC q8h) or fresh frozen plasma. Always adjust dosages for renal or hepatic impairment and monitor for adverse effects.

Key studies and consensus guidelines: 1) The 2013 AAFP Feline Vaccination Advisory Panel Report recommends FVRCP vaccination for all cats, with revaccination every 3 years for low-risk adults. 2) A study by Radford et al. (2007) in Veterinary Microbiology demonstrated the genetic diversity of FCV and the emergence of VS-FCV strains. 3) A study by Hurley et al. (2004) in JAVMA described an outbreak of VS-FCV in a shelter, highlighting the high mortality and need for strict biosecurity. 4) A randomized controlled trial by Mende et al. (2014) in Journal of Feline Medicine and Surgery showed that feline interferon-omega reduced clinical signs in cats with FCV infection. 5) The ISCAID guidelines (2019) for the management of feline upper respiratory tract disease recommend supportive care and judicious use of antibiotics. 6) A meta-analysis by Fernandez et al. (2017) in Veterinary Record found that vaccination reduces the severity of disease but does not prevent infection. 7) Studies on antiviral agents, such as nitazoxanide and ribavirin, have shown in vitro efficacy but lack clinical evidence. 8) The use of feline recombinant interferon-omega is supported by several studies, but it is not licensed in all countries. 9) A study by Coyne et al. (2006) in Veterinary Microbiology showed that cats can be persistently infected and shed virus for months, emphasizing the importance of isolation. 10) The ACVIM consensus statement on feline infectious diseases (2013) provides recommendations for diagnosis and management of FCV infection.